https://reurl.cc/4a88LV
路透社報導
Fosun-BioNTech COVID-19 vaccine completes China regulator review - media
SHANGHAI, July 15 (Reuters) - Chinese regulators have completed an expert
review of a COVID-19 mRNA vaccine developed by Germany's BioNTech (22UAy.DE)
and Fosun Pharma (600196.SS) and the shot is in the administration review
stage, Caixin reported, citing the Chinese company.
China hasn't approved any COVID-19 vaccine developed overseas but
greenlighted several domestic brands, administering 1.4 billion doses so far,
or two-fifths of the global total of 3.47 billion doses.
BioNTech Chief Executive Ugur Sahin said in April he expected its COVID-19
vaccine would win approval from the Chinese authorities "by June at the
latest."
BioNTech and Fosun did not immediately reply to Reuters' requests for comment.
The vaccine is on track to begin trial production in China at the end of
August, Caixin cited Fosun Pharma chairman Wu Yifang as saying at a
shareholders' meeting on Wednesday.
It said the vaccine would be used as a booster shot for people who have
received vaccines using inactivated viruses.
These are vaccines that use a coronavirus that cannot replicate in human
cells and include Sinovac's (SVA.O) COVID-19 shot.
簡單來說就是中國政府對BNT疫苗已經通過專家審查，進入行政審查並預計作為那些打過
科興、國藥的人的第三針加強劑，然後八月底復星在中國開始試生產BNT疫苗
復星：反正你最後都還是要打BNT的，為什麼不一開始就打BNT呢，ㄏㄏ
好險郭董跟GG已經完成簽約了，不然再過幾個月復星真的可能不賣台灣了....因為優先供給中國國內
只是這算是側面說中國國產疫苗算是不成功嗎?因為最後還是要打國外的疫苗XD